NCT02042001 - Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2015

Primary Completion Date

July 3, 2017

Study Completion Date

January 15, 2018

Conditions

Impaired CognitionDepression/AnxietyPoor Quality SleepQuality of LifeHIV-1 Infection

Interventions

DRUG

Immediate switch to TDF/FTC/RPV

DRUG

Switch to TDF/FTC/RPV after 24 weeks

Patients will continue current EFV-containing regimen up to week 24 and then will be switched to TDF/FTC/RPV

Trial Locations (5)

Clinic of Infectious Diseases, AO San Gerardo, Monza

Spedali Civili - University of Brescia, Brescia

Clinica di Malattie Infettive, Ospedale San Martino, Genova

AO San Paolo - University of Milan, Milan

Ospedale Amedeo di Savoia - University of Turin, Torino